Progress toward curing HIV infection with hematopoietic cell transplantation.

dc.contributor.author

Petz, Lawrence D

dc.contributor.author

Burnett, John C

dc.contributor.author

Li, Haitang

dc.contributor.author

Li, Shirley

dc.contributor.author

Tonai, Richard

dc.contributor.author

Bakalinskaya, Milena

dc.contributor.author

Shpall, Elizabeth J

dc.contributor.author

Armitage, Sue

dc.contributor.author

Kurtzberg, Joanne

dc.contributor.author

Regan, Donna M

dc.contributor.author

Clark, Pamela

dc.contributor.author

Querol, Sergio

dc.contributor.author

Gutman, Jonathan A

dc.contributor.author

Spellman, Stephen R

dc.contributor.author

Gragert, Loren

dc.contributor.author

Rossi, John J

dc.date.accessioned

2022-03-23T19:03:20Z

dc.date.available

2022-03-23T19:03:20Z

dc.date.issued

2015-01

dc.date.updated

2022-03-23T19:03:19Z

dc.description.abstract

HIV-1 infection afflicts more than 35 million people worldwide, according to 2014 estimates from the World Health Organization. For those individuals who have access to antiretroviral therapy, these drugs can effectively suppress, but not cure, HIV-1 infection. Indeed, the only documented case for an HIV/AIDS cure was a patient with HIV-1 and acute myeloid leukemia who received allogeneic hematopoietic cell transplantation (HCT) from a graft that carried the HIV-resistant CCR5-∆32/∆32 mutation. Other attempts to establish a cure for HIV/AIDS using HCT in patients with HIV-1 and malignancy have yielded mixed results, as encouraging evidence for virus eradication in a few cases has been offset by poor clinical outcomes due to the underlying cancer or other complications. Such clinical strategies have relied on HIV-resistant hematopoietic stem and progenitor cells that harbor the natural CCR5-∆32/∆32 mutation or that have been genetically modified for HIV-resistance. Nevertheless, HCT with HIV-resistant cord blood remains a promising option, particularly with inventories of CCR5-∆32/∆32 units or with genetically modified, human leukocyte antigen-matched cord blood.

dc.identifier

sccaa-8-109

dc.identifier.issn

1178-6957

dc.identifier.issn

1178-6957

dc.identifier.uri

https://hdl.handle.net/10161/24631

dc.language

eng

dc.publisher

Informa UK Limited

dc.relation.ispartof

Stem cells and cloning : advances and applications

dc.relation.isversionof

10.2147/sccaa.s56050

dc.subject

CCR5 mutation

dc.subject

CCR5-∆32/∆32 cord blood inventory

dc.subject

curing HIV infection

dc.subject

genetic modification of stem cells

dc.subject

hematopoietic cell transplantation

dc.title

Progress toward curing HIV infection with hematopoietic cell transplantation.

dc.type

Journal article

duke.contributor.orcid

Kurtzberg, Joanne|0000-0002-3370-0703

pubs.begin-page

109

pubs.end-page

116

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Pathology

pubs.organisational-group

Pediatrics

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Innovation & Entrepreneurship

pubs.organisational-group

Pediatrics, Transplant and Cellular Therapy

pubs.publication-status

Published

pubs.volume

8

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
p295 Petz.pdf
Size:
244.01 KB
Format:
Adobe Portable Document Format
Description:
Published version